Linvoseltamab Promising in High-Risk Smoldering Multiple Myeloma

(Medage today) – Toronto – Linvoseltamab (Lynozyfic) appeared effective in patients with multiple myeloma that cut at high risk (HR -SMM), according to preliminary data from phase II trials. With a median follow -up of 3.9 months among 19 evaluables …